SCHEMBL1395016

SCHEMBL1395016

O=C1CCCc2[nH]ncc21

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 12/20 0.41
PKN1 Q16512 1/20 0.40
PKN2 Q16513 1/20 0.40
PLK1 P53350 1/20 0.39
CSNK2A1 P68400 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
KCNH2 Q12809 2/20 0.38
CCNA2 P20248 2/20 0.38
CDK2 P24941 2/20 0.38
CCNA1 P78396 2/20 0.38
CYP2A6 P11509 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6036229 0.98 GRM4 (0.40) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL29590771 0.96 GRM4 (0.38) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL6476656 0.96 GRM4 (0.38) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL5944129 0.87
Water SCHEMBL6036672 0.84 GRM4 (0.36) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL31174052 0.81 PLK1 (0.35) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL6333956 0.75 CCNA2 (0.41) GRM4CCNA2CDK2CCNA1
SCHEMBL20919789 0.75 CDC7 (0.45) GRM4PKN1PKN2PLK1CSNK2A1
SCHEMBL13513362 0.71 GRM4 (0.42) GRM4KCNH2CCNA2CDK2CCNA1
SCHEMBL8025740 0.69 GRM4 (0.38) GRM4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069325-A2 ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES Serenex, Inc. (US) 2009-06-17 EP claimed
WO-2008024977-A2 ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO claimed
EP-0590558-B1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture THOMAE GMBH DR K (DE) 1995-12-06 EP claimed
US-5468766-A Analgesics, antipyretics, antiphlogistics DR. KARL THOMAE GMBH (DE) 1995-11-21 US claimed
EP-0590558-A1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture Dr. Karl Thomae GmbH (DE) 1994-04-06 EP claimed
JP-6211802-A None JP disclosed
US-20250326749-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2025-10-23 US disclosed
EP-4536655-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF Sionna Therapeutics Inc. (US) 2025-04-16 EP disclosed
CN-119677730-A Compounds, compositions, and methods of use thereof 希安纳医疗公司 2025-03-21 CN disclosed
EP-4423069-A1 INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2024-09-04 EP disclosed
US-12071411-B2 Inhibitors of HIF-2α and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2024-08-27 US disclosed
EP-0590558-B1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture THOMAE GMBH DR K (DE) 1995-12-06 EP disclosed
US-5468766-A Analgesics, antipyretics, antiphlogistics DR. KARL THOMAE GMBH (DE) 1995-11-21 US disclosed
US-5468766-A Analgesics, antipyretics, antiphlogistics DR. KARL THOMAE GMBH (DE) 1995-11-21 US disclosed
US-5468766-A Analgesics, antipyretics, antiphlogistics DR. KARL THOMAE GMBH (DE) 1995-11-21 US disclosed
JP-H06211802-A 1,5,6,7-TETRAHYDRO-4H-INDAZOL-4-ONES, ANALGESIC, ANTIPYRETIC AND ANTIPHLOGISTIC PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND THEIR PREPARATION DR KARL THOMAE GMBH 1994-08-02 JP disclosed
EP-0590558-A1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture Dr. Karl Thomae GmbH (DE) 1994-04-06 EP disclosed
EP-0590558-A1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture Dr. Karl Thomae GmbH (DE) 1994-04-06 EP disclosed
EP-0590558-A1 Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture Dr. Karl Thomae GmbH (DE) 1994-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLK, POLH GRM4 4270/4885PKN1 1870/4885PKN2 2321/4885
US-20250326749-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, SLC26A4, PKD2 GRM4 4662/4885PKN1 3266/4885PKN2 3198/4885
US-12071411-B2 Inhibitors of HIF-2α and methods of use thereof HIF1AN, HIF1A, EGLN2 GRM4 4484/4885PKN1 1258/4885PKN2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.